According to a recent LinkedIn post from AAVantgarde Bio, the company has brought on Philip Lao as Senior Vice President of Business Development. The post suggests that Lao will focus on expanding strategic partnerships and commercial opportunities for the firm’s pipeline of retinal therapeutics.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The LinkedIn post also points to in‑development programs targeting Usher 1B and Stargardt disease, indicating ongoing investment in inherited retinal disorder therapeutics. For investors, the appointment of a senior business development leader may signal a greater emphasis on partnership-driven growth, potential licensing deals, and future revenue streams tied to these clinical assets.